


Ask a doctor about a prescription for INVEGA 3 mg PROLONGED-RELEASE TABLETS
Package Leaflet: Information for the User
INVEGA 3 mg prolonged-release tablets
INVEGA 6 mg prolonged-release tablets
INVEGA 9 mg prolonged-release tablets
INVEGA 12 mg prolonged-release tablets
Paliperidone
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack:
INVEGA contains the active substance paliperidone, which belongs to a class of medicines called antipsychotics.
INVEGA is used to treat schizophrenia in adults and adolescents aged 15 years and older.
Schizophrenia is a disorder that causes symptoms such as hearing, seeing, or feeling things that do not exist, having false beliefs, being abnormally suspicious, being withdrawn, having disorganized speech, and a flattening of emotions and behavior. People with this disorder may also feel depressed, anxious, guilty, or tense.
INVEGA is also used to treat schizoaffective disorder in adults.
Schizoaffective disorder is a mental condition where a person experiences several of the symptoms of schizophrenia (listed in the previous paragraph) as well as symptoms of mood disorder (feeling elated, depressed, agitated, restless, insomnia, talkativeness, loss of interest in daily activities, excessive or reduced sleep or food intake, and recurring thoughts of suicide).
INVEGA can help alleviate the symptoms of your illness and prevent them from coming back.
Do not take INVEGA
Warnings and precautions
Talk to your doctor, pharmacist, or nurse before you start taking INVEGA.
If you have any of these diseases, please consult your doctor, as it may be necessary to adjust your dose or keep you under observation for a while.
Because it has been rarely observed in patients treated with INVEGA a dangerously low number of a type of white blood cells necessary to fight infections in the blood, your doctor may check your white blood cell count.
INVEGA may cause you to gain weight. Significant weight gain can negatively affect your health. Your doctor will regularly monitor your weight.
In patients treated with INVEGA, diabetes mellitus or worsening of pre-existing diabetes mellitus has been observed, your doctor should check for signs of high blood sugar. In patients with pre-existing diabetes mellitus, blood sugar should be regularly monitored.
During eye surgery for cataracts, the pupil (the black circle in the center of the eye) may not increase in size as needed. Additionally, the iris (the colored part of the eye) may become flaccid during surgery, which can cause eye damage. If you are considering eye surgery, make sure to inform your ophthalmologist that you are using this medicine.
Children and adolescents
INVEGA should not be given to children and adolescents under 15 years of age for the treatment of schizophrenia.
INVEGA should not be given to children and adolescents under 18 years of age for the treatment of schizoaffective disorder.
This is because it is not known if INVEGA is safe or effective in this age group.
Taking INVEGA with other medicines
Tell your doctor or pharmacist if you are using or have recently used other medicines.
Abnormalities in heart function may appear when taking this medicine with other medicines for controlling heart rhythm or other medicines such as antihistamines, antimalarials, or antipsychotics.
Since this medicine acts mainly on the brain, this medicine may interfere with other medicines (or alcohol) that also act on it, due to the sum of effects on brain function.
This medicine may lower blood pressure, so you should be careful if you take this medicine with other medicines that also lower blood pressure.
This medicine may reduce the effect of medicines for Parkinson's disease and restless legs syndrome (e.g., levodopa).
The effects of this medicine may be affected if you take medicines that influence the speed of intestinal movement (e.g., metoclopramide).
A reduction in the dose of this medicine should be considered when this medicine is administered at the same time as valproate.
The use of oral risperidone with this medicine is not recommended, as this combination may cause an increase in side effects.
INVEGA with alcohol
You should avoid consuming alcohol during treatment with this medicine.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.
You should not take this medicine during pregnancy unless you have discussed it with your doctor.
The following symptoms may occur in newborn babies of mothers who have been treated with paliperidone in the last trimester of pregnancy (last three months of pregnancy): tremor, stiffness and/or muscle weakness, somnolence, agitation, breathing problems, and feeding difficulties. If your baby develops any of these symptoms, you should contact your doctor.
You should not take this medicine during breastfeeding.
Driving and using machines
During treatment with this medicine, dizziness and vision problems (see section 4, Possible side effects) may occur. This should be taken into account when maximum attention is required, for example, when driving or operating machinery.
The 3 mg INVEGA tablet contains lactose
The 3 mg tablet of this medicine contains lactose, a type of sugar. If your doctor has told you that you have an intolerance to some sugars, talk to them before taking this medicine.
INVEGA contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per dose; it is essentially "sodium-free".
Follow exactly the administration instructions of this medicine given by your doctor, pharmacist, or nurse.
Use in adults
The recommended dose in adults is 6 mg once daily in the morning. Your doctor may increase or decrease it within the dosage range of 3 mg to 12 mg once daily in case of schizophrenia or 6 mg to 12 mg once daily in case of schizoaffective disorder. This depends on how well the medicine works for you.
Use in adolescents
The recommended starting dose for the treatment of schizophrenia in adolescents aged 15 years and older is 3 mg once daily taken in the morning.
For adolescents who weigh 51 kg or more, the dose may be increased within the range of 6 mg to 12 mg once daily.
For adolescents who weigh less than 51 kg, the dose may be increased to 6 mg once daily.
Your doctor will decide how much you should take. The amount you take depends on how well the medicine works for you.
How and when to take INVEGA
This medicine should be taken by mouth, swallowed whole with water or other liquids. It should not be chewed, broken, or crushed.
This medicine should be taken in the mornings with breakfast or on an empty stomach, but each day in the same way. Do not alternate between taking the medicine one day with breakfast and the next day on an empty stomach.
The active substance, paliperidone, is dissolved once swallowed, and the tablet coating is eliminated from the body through the feces.
Patient with kidney problems
Your doctor may adjust your dose of this medicine according to your kidney function.
Elderly
Your doctor may reduce your dose of medicine if your kidney function is reduced.
If you take more INVEGA than you should
Contact your doctor immediately. You may experience somnolence, fatigue, abnormal body movements, problems standing and walking, dizziness due to low blood pressure, and changes in heartbeats.
If you forget to take INVEGA
Do not take a double dose to make up for forgotten doses. If you forget a dose, take the next dose the next day. If you forget two doses or more, contact your doctor.
If you stop taking INVEGA
Do not stop taking this medicine, as you will lose the effects of the medicine. Do not stop taking this medicine unless your doctor tells you to, as your symptoms may come back.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
Report immediately to your doctor if:
Very common: may affect more than 1 in 10 patients
Common adverse effects: may affect up to 1 in 10 patients
Uncommon adverse effects: may affect up to 1 in 100 patients
Rare adverse effects: may affect up to 1 in 1,000 patients
Unknown frequency: cannot be estimated from the available data
The following adverse effects have appeared with the use of another medicine called risperidone, which is very similar to paliperidone, so it is also expected to appear with INVEGA: sleep-related eating disorder, other types of cerebrovascular problems, and crackling sounds in the lungs. Eye problems may also appear during cataract surgery. During cataract surgery, a condition called intraoperative floppy iris syndrome (IFIS) may occur if you are taking or have taken INVEGA. If you need to undergo cataract surgery, make sure to inform your ophthalmologist if you are taking or have taken this medicine.
Additional adverse effects in adolescents
Adolescents generally experienced adverse effects similar to those found in adults, except for the following adverse effects that were detected more frequently:
Reporting of adverse effects
If you experience adverse effects, consult your doctor, pharmacist, or nurse, even if they are adverse effects that do not appear in this leaflet. You can also report them directly through the national reporting system included in Appendix V. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date that appears on the blister/pack and on the carton after EXP. The expiration date is the last day of the month indicated.
Bottles: Do not store above 30°C. Keep the bottle tightly closed to protect it from moisture.
Blister packs: Do not store above 30°C. Store in the original packaging to protect it from moisture.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of the packaging and any unused medicines. This will help protect the environment.
Composition of INVEGA
The active ingredient is paliperidone.
Each 3 mg prolonged-release tablet of INVEGA contains 3 mg of paliperidone.
Each 6 mg prolonged-release tablet of INVEGA contains 6 mg of paliperidone.
Each 9 mg prolonged-release tablet of INVEGA contains 9 mg of paliperidone.
Each 12 mg prolonged-release tablet of INVEGA contains 12 mg of paliperidone.
The other ingredients are:
Coated tablet core:
Polyethylene oxide 200K
Sodium chloride Povidone (K29-32)
Stearic acid
Butylhydroxytoluene (E321)
Ferric oxide (Yellow) (E172) (only 3 and 12 mg tablets)
Polyethylene oxide 7000K
Ferric oxide (Red) (E172)
Hydroxyethyl cellulose
Polyethylene glycol 3350
Cellulose acetate
Iron oxide (Black) (E172) (only 9 mg tablets)
Colored coating:
Hypromellose
Titanium dioxide (E171)
Polyethylene glycol 400 (only 6, 9, and 12 mg tablets)
Ferric oxide (Yellow) (E172) (only 6 and 12 mg tablets)
Ferric oxide (Red) (E172) (only 6 and 9 mg tablets)
Lactose monohydrate (only 3 mg tablets)
Triacetin (only 3 mg tablets)
Carnauba wax
Printing ink:
Iron oxide (Black) (E172) Propylene glycol
Hypromellose
Product Appearance and Container Contents
The INVEGA prolonged-release tablets are capsule-shaped. The 3 mg tablets are white and engraved with “PAL 3”, the 6 mg tablets are beige and engraved with “PAL 6”, the 9 mg tablets are pink and engraved with “PAL 9”, and the 12 mg tablets are dark yellow and engraved with “PAL12”. All tablets are marketed in the following presentations:
Only certain package sizes may be marketed.
Marketing Authorization Holder
Janssen-Cilag International NV Turnhoutseweg 30
B-2340 Beerse
Belgium
Manufacturer
Janssen-Cilag SpA Via C. Janssen
04100 Borgo San Michele
Latina
Italy
For further information on this medicinal product, please contact the local representative of the marketing authorization holder:
| Lithuania UAB “JOHNSON & JOHNSON” Tel: +370 5 278 68 88 | |
| Luxembourg Janssen-Cilag NV Tel: +32 14 64 94 11 | |
| Hungary JANSSEN-CILAG Kft. Tel: +36 1 884 2858 | |
| Malta AM MANGION LTD. Tel: +356 2397 6000 | |
| Netherlands JANSSEN-CILAG B.V. Tel: +31 76 711 1111 | |
| Norway JANSSEN-CILAG AS Tel: +47 24 12 65 00 | |
Greece JANSSEN-CILAG Φαρμακευτικ? Α.Ε.Β.Ε Tel: +30 210 80 90 000 | Austria Janssen-Cilag Pharma GmbH Tel: +43 1 610 300 | |
| Poland JANSSEN–CILAG Polska Sp. z o.o. Tel: +48 22 237 60 00 | |
| Portugal Janssen-Cilag Farmacêutica, Lda. Tel: +351 214 368 600 | |
| Romania Johnson & Johnson România SRL Tel: +40 21 207 1800 | |
| Slovenia Johnson & Johnson d.o.o. Tel: +386 1 401 18 00 | |
| Slovak Republic Johnson & Johnson, s.r.o. Tel: +421 232 408 400 | |
| Finland JANSSEN-CILAG OY Tel: +358 207 531 300 | |
| Sweden JANSSEN-CILAG AB Tel: +46 8 626 50 00 | |
| United Kingdom JANSSEN-CILAG Ltd. Tel: +44 1 494 567 444 |
Date of Last Revision of this Leaflet: MM/YYYY
Other Sources of Information
Detailed information on this medicinal product is available on the European Medicines Agency website http://www.ema.europa.eu
The average price of INVEGA 3 mg PROLONGED-RELEASE TABLETS in October, 2025 is around 27.58 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for INVEGA 3 mg PROLONGED-RELEASE TABLETS – subject to medical assessment and local rules.